{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:36:00Z","timestamp":1792888560787,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00210-026-05632-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:03:15Z","timestamp":1783573395000},"page":"21713-21724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paclitaxel in oncology: balancing anticancer efficacy with potential carcinogenic risks and resistance mechanisms"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6973-8951","authenticated-orcid":false,"given":"Abdullah","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2877-9442","authenticated-orcid":false,"given":"Barina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8719-4738","authenticated-orcid":false,"given":"Ahmed Reda","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-6339","authenticated-orcid":false,"given":"Mostafa","family":"Abdelhakiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"5632_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100918","volume":"43","author":"HA Abouzeid","year":"2025","unstructured":"Abouzeid HA, Kassem L, Liu X, Abuelhana A (2025) Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies. Cancer Treat Res Commun 43:100918. https:\/\/doi.org\/10.1016\/j.ctarc.2025.100918","journal-title":"Cancer Treat Res Commun"},{"key":"5632_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117611","volume":"291","author":"A Acharya","year":"2025","unstructured":"Acharya A, Roy N, Newaskar V, Rai A, Ghosh A, Nagpure M et al (2025) Topoisomerase II-targeting anticancer clinical candidates and drugs: A critical analysis, unravelling molecular medicinal insights and promising research roadmap. Eur J Med Chem 291:117611. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117611","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5632_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12935-024-03415-0","volume":"24","author":"AI Alalawy","year":"2024","unstructured":"Alalawy AI (2024) Key genes and molecular mechanisms related to paclitaxel resistance. Cancer Cell Int 24(1):244. https:\/\/doi.org\/10.1186\/s12935-024-03415-0","journal-title":"Cancer Cell Int"},{"key":"5632_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114434","volume":"445","author":"AG Alkhathami","year":"2025","unstructured":"Alkhathami AG, Pallathadka H, Shah S, Ganesan S, Sharma A, Devi S, Mustafa YF, Alasheqi MQ, Kadhim AJ, Zwamel AH (2025) Mechanisms behind the LncRNAs-mediated regulation of paclitaxel (PTX) resistance in human malignancies. Exp Cell Res 445:114434. https:\/\/doi.org\/10.1016\/j.yexcr.2025.114434","journal-title":"Exp Cell Res"},{"key":"5632_CR5","doi-asserted-by":"crossref","unstructured":"Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT (2019) Chapter three - paclitaxel profiles of drug substances, excipients and related methodology, vol 44. Academic Press, pp 205\u2013238","DOI":"10.1016\/bs.podrm.2018.11.001"},{"issue":"6","key":"5632_CR6","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","volume":"174","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Cantley LC (2018) The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell 174(6):1347\u20131360. https:\/\/doi.org\/10.1016\/j.cell.2018.08.027","journal-title":"Cell"},{"key":"5632_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101223","volume":"81","author":"GL Beretta","year":"2025","unstructured":"Beretta GL, Cassinelli G, Rossi G, Azzariti A, Corbeau I, Tosi D et al (2025) Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation, and drug delivery strategies. Drug Resist Updat 81:101223. https:\/\/doi.org\/10.1016\/j.drup.2025.101223","journal-title":"Drug Resist Updat"},{"key":"5632_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8308179","volume":"2016","author":"UB Bhatnagar","year":"2016","unstructured":"Bhatnagar UB, Singh D, Glazyrin A, Moormeier J (2016) Paclitaxel induced MDS and AML: a case report and literature review. Case Rep Oncol Med 2016:1\u20135. https:\/\/doi.org\/10.1155\/2016\/8308179","journal-title":"Case Rep Oncol Med"},{"issue":"7","key":"5632_CR9","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kr\u00e4ling BM, Shi B, Marshall B, O\u2019Reilly MS et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878\u20131886","journal-title":"Cancer Res"},{"key":"5632_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/oncolo\/oyac206","volume":"28","author":"K Christiansen","year":"2023","unstructured":"Christiansen K, Buswell L, Fadelu T (2023) A systematic review of patient education strategies for oncology patients in low- and middle-income countries. The Oncologist 28(1):2\u201311. https:\/\/doi.org\/10.1093\/oncolo\/oyac206","journal-title":"Oncologist"},{"key":"5632_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/mutage\/16.1.79","volume":"16","author":"KS Cunha","year":"2001","unstructured":"Cunha KS (2001) Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster. Mutagenesis 16:79\u201384. https:\/\/doi.org\/10.1093\/mutage\/16.1.79","journal-title":"Mutagenesis"},{"issue":"2","key":"5632_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-23-1073","volume":"14","author":"M Di Bona","year":"2024","unstructured":"Di Bona M, Bakhoum SF (2024) Micronuclei and cancer. Cancer Discov 14(2):214\u2013226. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1073","journal-title":"Micronuclei and cancer. Cancer Discov"},{"key":"5632_CR13","doi-asserted-by":"publisher","unstructured":"Digue L, Orsire T, De Mo M, Matti MG, Depetris D, Duffaud F, Favre R, Botta A (1999) Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. Environ Mol Mutagen 34:269\u2013278. https:\/\/doi.org\/10.1002\/(SICI)1098-2280(1999)34:4%3C269::AID-EM7%3E3.0.CO;2-D","DOI":"10.1002\/(SICI)1098-2280(1999)34:4%3C269::AID-EM7%3E3.0.CO;2-D"},{"key":"5632_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1553-x","volume":"15","author":"J Du","year":"2015","unstructured":"Du J, Li B, Fang Y, Liu Y, Wang Y, Li J, Zhou W, Wang X (2015) Overexpression of class III \u03b2-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer 15:536. https:\/\/doi.org\/10.1186\/s12885-015-1553-x","journal-title":"BMC Cancer"},{"issue":"19","key":"5632_CR15","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.4161\/15384101.2014.949083","volume":"13","author":"M Fischer","year":"2014","unstructured":"Fischer M, Steiner L, Engeland K (2014) The transcription factor p53: not a repressor, solely an activator. Cell Cycle 13(19):3037\u20133058. https:\/\/doi.org\/10.4161\/15384101.2014.949083","journal-title":"Cell Cycle"},{"key":"5632_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Fran\u00e7a","year":"2024","unstructured":"Fran\u00e7a GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, Rao A, Patel AS, Misirlioglu S, Barkley D, Tang KH, Dolgalev I, Liberman DA, Avital G, Kuperwaser F, Chiodin M, Levine DA, Papagiannakopoulos T, Marusyk A, Lionnet T, Yanai I (2024) Cellular adaptation to cancer therapy along a resistance continuum. Nature 631:876\u2013883. https:\/\/doi.org\/10.1038\/s41586-024-07690-9","journal-title":"Nature"},{"issue":"15","key":"5632_CR17","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1242\/jcs.039719","volume":"122","author":"KE Gascoigne","year":"2009","unstructured":"Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122(15):2579\u20132585. https:\/\/doi.org\/10.1242\/jcs.039719","journal-title":"J Cell Sci"},{"issue":"1","key":"5632_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP\u2013dependent transporters. Nat Rev Cancer 2(1):48\u201358. https:\/\/doi.org\/10.1038\/nrc706","journal-title":"Nat Rev Cancer"},{"issue":"31","key":"5632_CR19","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794\u20137803. https:\/\/doi.org\/10.1200\/JCO.2005.04.937","journal-title":"J Clin Oncol"},{"issue":"7","key":"5632_CR20","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3390\/biomedicines11072000","volume":"11","author":"MS Hassan","year":"2023","unstructured":"Hassan MS, Awasthi N, Ponna S, Von Holzen U (2023) Nab-paclitaxel in the treatment of gastrointestinal cancers\u2014improvements in clinical efficacy and safety. Biomedicines 11(7):2000. https:\/\/doi.org\/10.3390\/biomedicines11072000","journal-title":"Biomedicines"},{"issue":"22","key":"5632_CR21","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","volume":"10","author":"TJ Herzog","year":"2004","unstructured":"Herzog TJ (2004) Recurrent ovarian cancer. Clin Cancer Res 10(22):7439\u20137449. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0683","journal-title":"Clin Cancer Res"},{"issue":"24","key":"5632_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","volume":"83","author":"FA Holmes","year":"1991","unstructured":"Holmes FA, Walters RS, Theriault RL, Buzdar AU, Frye DK, Hortobagyi GN et al (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. JNCI J Natl Cancer Inst 83(24):1797\u20131805. https:\/\/doi.org\/10.1093\/jnci\/83.24.1797-a","journal-title":"JNCI J Natl Cancer Inst"},{"key":"5632_CR23","unstructured":"Ismail U, Killeen RB (2023) Taxane toxicity. StatPearls - NCBI Bookshelf"},{"key":"5632_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M (2025) Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol 18:36. https:\/\/doi.org\/10.1186\/s13045-025-01688-0","journal-title":"J Hematol Oncol"},{"key":"5632_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253\u2013265. https:\/\/doi.org\/10.1038\/nrc1317","journal-title":"Nat Rev Cancer"},{"key":"5632_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/413076","volume":"2015","author":"NC Kampan","year":"2015","unstructured":"Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M (2015) Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Res Int 2015:1\u201321. https:\/\/doi.org\/10.1155\/2015\/413076","journal-title":"BioMed Res Int"},{"issue":"9","key":"5632_CR27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.emboj.7600196","volume":"23","author":"M Koshiji","year":"2004","unstructured":"Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE (2004) HIF-1\u03b1 induces cell cycle arrest by functionally counteracting Myc. EMBO J 23(9):1949\u20131956. https:\/\/doi.org\/10.1038\/sj.emboj.7600196","journal-title":"EMBO J"},{"issue":"5","key":"5632_CR28","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1007\/s12011-022-03125-6","volume":"200","author":"Y\u00c7 Kumbul","year":"2022","unstructured":"Kumbul Y\u00c7, Naz\u0131ro\u011flu M (2022) Paclitaxel promotes oxidative stress\u2013mediated human laryngeal squamous tumor cell death through the stimulation of calcium and zinc signaling pathways: no synergic action of melatonin. Biol Trace Elem Res 200(5):2084\u20132098. https:\/\/doi.org\/10.1007\/s12011-022-03125-6","journal-title":"Biol Trace Elem Res"},{"issue":"5","key":"5632_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104355","volume":"30","author":"I Lima","year":"2025","unstructured":"Lima I, Borges F, Pombinho A, Chavarria D (2025) The spindle assembly checkpoint: molecular mechanisms and kinase-targeted drug discovery. Drug Discov Today 30(5):104355. https:\/\/doi.org\/10.1016\/j.drudis.2025.104355","journal-title":"Drug Discov Today"},{"key":"5632_CR30","doi-asserted-by":"publisher","unstructured":"Lin S, Peng T, Meng Y, Cao C, Gao P, Wu P et al (2022) Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis. Aging 14(4):1959\u20131982. https:\/\/doi.org\/10.18632\/aging.203919","DOI":"10.18632\/aging.203919"},{"issue":"28","key":"5632_CR31","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325\u20133348. https:\/\/doi.org\/10.1200\/JCO.20.01399","journal-title":"J Clin Oncol"},{"issue":"11","key":"5632_CR32","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/cancers12113323","volume":"12","author":"SM Maloney","year":"2020","unstructured":"Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR (2020) Mechanisms of taxane resistance. Cancers 12(11):3323. https:\/\/doi.org\/10.3390\/cancers12113323","journal-title":"Mechanisms of taxane resistance. Cancers"},{"issue":"7","key":"5632_CR33","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jog.15954","volume":"50","author":"A Matsuoka","year":"2024","unstructured":"Matsuoka A, Tate S, Nishikimi K, Otsuka S, Usui H, Tajima S et al (2024) Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series. J Obstet Gynaecol Res 50(7):1148\u20131154. https:\/\/doi.org\/10.1111\/jog.15954","journal-title":"J Obstet Gynaecol Res"},{"key":"5632_CR34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1999.17.6.1786","volume":"17","author":"M Monz\u00f3","year":"1999","unstructured":"Monz\u00f3 M, Rosell R, S\u00e1nchez JJ, Lee JS, O\u2019Brate A, Gonz\u00e1lez-Larriba JL, Alberola V, Lorenzo JC, N\u00fa\u00f1ez L, Ro JY, Mart\u00edn C (1999) Paclitaxel resistance in non\u2013small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17:1786\u20131786. https:\/\/doi.org\/10.1200\/JCO.1999.17.6.1786","journal-title":"J Clin Oncol"},{"key":"5632_CR35","doi-asserted-by":"publisher","unstructured":"Morton LM, Curtis RE, Linet MS, Schonfeld SJ, Advani PG, Dalal NH et al (2023) Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000\u20132018. eClinicalMedicine 61:102060. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102060","DOI":"10.1016\/j.eclinm.2023.102060"},{"key":"5632_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G (2021) Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat 54:100742. https:\/\/doi.org\/10.1016\/j.drup.2020.100742","journal-title":"Drug Resist Updat"},{"key":"5632_CR37","unstructured":"National Cancer Institute (n.d.) Chemotherapy to treat cancer [Internet]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/chemotherapy"},{"issue":"2","key":"5632_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jtcvs.2003.09.033","volume":"127","author":"DM Nguyen","year":"2004","unstructured":"Nguyen DM, Chen GA, Reddy R, Tsai W, Schrump WD, Cole G et al (2004) Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase\/protein kinase B (Akt)\u2013mediated signaling pathway. J Thorac Cardiovasc Surg 127(2):365\u2013375. https:\/\/doi.org\/10.1016\/j.jtcvs.2003.09.033","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"5632_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","volume":"108","author":"C Nilsson","year":"2022","unstructured":"Nilsson C, Linde F, Huleg\u00e5rdh E, Garelius H, Lazarevic V, Antunovic P et al (2022) Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica 108(4):1015\u20131025. https:\/\/doi.org\/10.3324\/haematol.2022.281233","journal-title":"Haematologica"},{"key":"5632_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36073-9","volume":"13","author":"K Nishida","year":"2023","unstructured":"Nishida K, Matsumura K, Tamura M, Nakamichi T, Shimamori K, Kuragano M, Kabir A, Kakugo A, Kotani S, Nishishita N, Tokuraku K (2023) Effects of three microtubule-associated proteins (MAP2, MAP4, and Tau) on microtubules\u2019 physical properties and neurite morphology. Sci Rep 13:8870. https:\/\/doi.org\/10.1038\/s41598-023-36073-9","journal-title":"Sci Rep"},{"key":"5632_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090786","volume":"13","author":"M Nunes","year":"2024","unstructured":"Nunes M, Bartosch C, Abreu MH, Richardson A, Almeida R, Ricardo S (2024) Deciphering the molecular mechanisms behind drug resistance in ovarian cancer to unlock efficient treatment options. Cells 13:786. https:\/\/doi.org\/10.3390\/cells13090786","journal-title":"Cells"},{"key":"5632_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1491394","volume":"12","author":"R Pun","year":"2025","unstructured":"Pun R, North BJ (2025) Role of spindle assembly checkpoint proteins in gametogenesis and embryogenesis. Front Cell Dev Biol 12:1491394. https:\/\/doi.org\/10.3389\/fcell.2024.1491394","journal-title":"Front Cell Dev Biol"},{"key":"5632_CR43","doi-asserted-by":"publisher","unstructured":"Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). Wood AJJ, editor. N Engl J Med 332(15):1004\u20131014. https:\/\/doi.org\/10.1056\/NEJM199504133321507","DOI":"10.1056\/NEJM199504133321507"},{"issue":"24","key":"5632_CR44","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer. N Engl J Med 355(24):2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"issue":"1","key":"5632_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40001-024-01657-2","volume":"29","author":"P Sati","year":"2024","unstructured":"Sati P, Sharma E, Dhyani P, Attri DC, Rana R, Kiyekbayeva L et al (2024) Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. Eur J Med Res 29(1):90. https:\/\/doi.org\/10.1186\/s40001-024-01657-2","journal-title":"Eur J Med Res"},{"issue":"5698","key":"5632_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/277665a0","volume":"277","author":"PB Schiff","year":"1979","unstructured":"Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665\u2013667. https:\/\/doi.org\/10.1038\/277665a0","journal-title":"Nature"},{"key":"5632_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13330-2","volume":"24","author":"M Schmidt","year":"2024","unstructured":"Schmidt M, Vernooij R, Van Nuland M, Smeijsters E, Devriese L, Mohammad NH, Hermens T, Stammers J, Swart C, Egberts T, Haitjema S, Lammers L (2024) Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival. BMC Cancer 24:1553. https:\/\/doi.org\/10.1186\/s12885-024-13330-2","journal-title":"BMC Cancer"},{"key":"5632_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114036","volume":"385","author":"S Seyam","year":"2025","unstructured":"Seyam S, Alallam B, Harif Fadzilah N, Abd KE (2025) Advances in paclitaxel nanoformulations: A systematic review of in vivo therapeutic efficacy and safety enhancements. J Control Release 385:114036. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114036","journal-title":"J Control Release"},{"issue":"4","key":"5632_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3892\/ijo.2011.1297","volume":"40","author":"M Shimomura","year":"2012","unstructured":"Shimomura M, Yaoi T, Itoh K, Kato D, Terauchi K, Shimada J et al (2012) Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. Int J Oncol 40(4):995\u20131004. https:\/\/doi.org\/10.3892\/ijo.2011.1297","journal-title":"Int J Oncol"},{"key":"5632_CR50","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41401-021-00847-6","volume":"43","author":"C Shu","year":"2022","unstructured":"Shu C, Zheng X, Wuhafu A, Cicka D, Doyle S, Niu Q, Fan D, Qian K, Ivanov AA, Du Y, Mo X, Fu H (2022) Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta Pharmacol Sin 43:2419\u20132428. https:\/\/doi.org\/10.1038\/s41401-021-00847-6","journal-title":"Acta Pharmacol Sin"},{"key":"5632_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010211","volume":"16","author":"S Singh","year":"2024","unstructured":"Singh S, Singh AP, Mitra R (2024) Cancer-associated fibroblasts: major co-conspirators in tumor development. Cancers (Basel) 16:211. https:\/\/doi.org\/10.3390\/cancers16010211","journal-title":"Cancers (Basel)"},{"key":"5632_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/plants10030569","volume":"10","author":"J \u0160kubn\u00edk","year":"2021","unstructured":"\u0160kubn\u00edk J, Pavl\u00ed\u010dkov\u00e1 V, Ruml T, Rimpelov\u00e1 S (2021) Current perspectives on taxanes: focus on their bioactivity, delivery and combination therapy. Plants (Basel) 10:569. https:\/\/doi.org\/10.3390\/plants10030569","journal-title":"Plants (Basel)"},{"issue":"7","key":"5632_CR53","doi-asserted-by":"publisher","first-page":"e00648","DOI":"10.1128\/MCB.00648-20","volume":"41","author":"ER Smith","year":"2021","unstructured":"Smith ER, Leal J, Amaya C, Li B, Xu XX (2021) Nuclear lamin A\/C expression is a key determinant of paclitaxel sensitivity. Mol Cell Biol 41(7):e00648\u2013e00620. https:\/\/doi.org\/10.1128\/MCB.00648-20","journal-title":"Mol Cell Biol"},{"key":"5632_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100881","volume":"65","author":"ER Smith","year":"2022","unstructured":"Smith ER, Wang JQ, Yang DH, Xu XX (2022 Dec) Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat 65:100881. https:\/\/doi.org\/10.1016\/j.drup.2022.100881","journal-title":"Drug Resist Updat"},{"key":"5632_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 10:174. https:\/\/doi.org\/10.3389\/fnmol.2017.00174","journal-title":"Front Mol Neurosci"},{"issue":"6149","key":"5632_CR56","doi-asserted-by":"publisher","first-page":"1240104","DOI":"10.1126\/science.1240104","volume":"341","author":"J Swift","year":"2013","unstructured":"Swift J, Ivanovska IL, Buxboim A, Harada T, Dingal PCDP, Pinter J et al (2013) Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science 341(6149):1240104. https:\/\/doi.org\/10.1126\/science.1240104","journal-title":"Science"},{"key":"5632_CR57","unstructured":"U.S. Food and Drug Administration. Paclitaxel, n.d."},{"issue":"14","key":"5632_CR58","doi-asserted-by":"publisher","first-page":"R591","DOI":"10.1016\/j.cub.2008.06.012","volume":"18","author":"G Varetti","year":"2008","unstructured":"Varetti G, Musacchio A (2008) The spindle assembly checkpoint. Curr Biol 18(14):R591\u2013R595. https:\/\/doi.org\/10.1016\/j.cub.2008.06.012","journal-title":"Curr Biol"},{"issue":"18","key":"5632_CR59","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"1","key":"5632_CR60","doi-asserted-by":"publisher","first-page":"10151","DOI":"10.1038\/s41467-024-54577-4","volume":"15","author":"TC Wang","year":"2024","unstructured":"Wang TC, Abolghasemzade S, McKee BP, Singh I, Pendyala K, Mohajeri M et al (2024) Matrix stiffness drives drop like nuclear deformation and lamin A\/C tension-dependent YAP nuclear localization. Nat Commun 15(1):10151. https:\/\/doi.org\/10.1038\/s41467-024-54577-4","journal-title":"Nat Commun"},{"key":"5632_CR61","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA (2014) How taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25:2677\u20132681. https:\/\/doi.org\/10.1091\/mbc.e14-04-0916","journal-title":"Mol Biol Cell"},{"key":"5632_CR62","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.4103\/jcrt.jcrt_1982_22","volume":"19","author":"S Wu","year":"2023","unstructured":"Wu S, Xiong T, Guo S, Zhu C, He J, Wang S (2023) An up-to-date view of paclitaxel-induced peripheral neuropathy. J Cancer Res Ther 19:1501\u20131508. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1982_22","journal-title":"J Cancer Res Ther"},{"issue":"8","key":"5632_CR63","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/ijms18081733","volume":"18","author":"CP Yang","year":"2017","unstructured":"Yang CP, Horwitz S (2017) Taxol\u00ae: the first microtubule stabilizing agent. Int J Mol Sci 18(8):1733. https:\/\/doi.org\/10.3390\/ijms18081733","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5632_CR64","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1525-1438.2007.01185.x","volume":"18","author":"S Yeasmin","year":"2008","unstructured":"Yeasmin S, Nakayama K, Ishibashi M, Oride A, Katagiri A, Purwana IN et al (2008) Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review. Int J Gynecol Cancer 18(6):1371\u20131376. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.01185.x","journal-title":"Int J Gynecol Cancer"},{"key":"5632_CR65","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cm.21154","volume":"70","author":"S Yin","year":"2013","unstructured":"Yin S, Zeng C, Hari M, Cabral F (2013) Paclitaxel resistance by random mutagenesis of \u03b1\u2010tubulin. Cytoskeleton (Hoboken) 70:849\u2013862. https:\/\/doi.org\/10.1002\/cm.21154","journal-title":"Cytoskeleton (Hoboken)"},{"issue":"1","key":"5632_CR66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","volume":"16","author":"A Zafar","year":"2025","unstructured":"Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A (2025) Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol 16(1):607. https:\/\/doi.org\/10.1007\/s12672-025-02198-8","journal-title":"Discov Oncol"},{"issue":"21","key":"5632_CR67","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.3390\/molecules27217183","volume":"27","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Tang Y, Tang X, Wang Y, Zhang Z, Yang H (2022) Paclitaxel induces the apoptosis of prostate cancer cells via ROS-mediated HIF-1\u03b1 expression. Molecules 27(21):7183. https:\/\/doi.org\/10.3390\/molecules27217183","journal-title":"Molecules"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05632-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:02:20Z","timestamp":1792886540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05632-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":67,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5632"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05632-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Does not apply. There was no involvement of new human participants in this study.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not apply. There was no involvement of new human participants in this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}